For laboratory and research use only. Not for human consumption.
Hormonal

Lanreotide

Also known as: Somatuline, Somatuline Depot

FDA Approved
Share:
Last reviewed

Key Facts: Lanreotide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - Acromegaly (2007), GEP-NETs (2014) and carcinoid syndrome (2017). 2026 supply note: Cipla's generic lanreotide, made under contract by Pharmathen in Greece, was recalled in early 2026 (lack of sterility assurance, Class II) and the Pharmathen site was reported placed under an FDA import alert in April 2026. Ipsen's Somatuline Depot is a separate product and Ipsen said in January 2026 it could supply patient needs.
Banned in Sport (WADA)
Not on the WADA Prohibited List (2026).
Administration
Deep subcutaneous injection
Typical Dose
60-120 mg every 4 weeks
Frequency
Every 4 weeks
Duration
Long-term / chronic use
Also Known As
Somatuline, Somatuline Depot

How does Lanreotide work?

Like octreotide, lanreotide binds the somatostatin receptor family with a strong preference for SSTR2 and SSTR5 and weak binding to SSTR1, SSTR3, and SSTR4. Hitting SSTR2 and SSTR5 on pituitary cells suppresses growth hormone release, which lowers IGF-1 and controls acromegaly. On neuroendocrine tumor cells, which often carry plenty of these same receptors, the drug both reduces hormone over-secretion and exerts a direct antiproliferative, growth-slowing effect. The supersaturated gel formulation forms a depot under the skin that releases the peptide slowly, so a single injection lasts about four weeks. The clinical logic is identical to octreotide: a stable, receptor-selective stand-in for a hormone the body destroys in minutes.

What does the research show?

Lanreotide has solid human trial evidence, not just preclinical data. The landmark CLARINET phase 3 trial, published in the New England Journal of Medicine in 2014, randomized over 200 patients with metastatic grade 1 or 2 enteropancreatic neuroendocrine tumors and showed lanreotide cut the risk of progression or death by 53 percent, with progression-free survival not reached versus about 18 months on placebo. That result made it one of the first somatostatin analogs proven to actually slow neuroendocrine tumor growth, not just ease symptoms. In acromegaly, multicenter studies show it normalizes IGF-1 and lowers growth hormone in a substantial fraction of patients, comparable to octreotide. Side effects mirror the class: diarrhea, gallstones, and injection-site reactions. The evidence base is mature and the drug is widely used in oncology and endocrinology.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

What doses have been studied?

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

60-120 mg every 4 weeks

Range

60-120 mg per administration

Frequency

Every 4 weeks

A long-acting somatostatin analog, marketed as Somatuline Depot.

Research Dosingⓘ

Scientific studies

FDA-approved dosing

Doses from Studies

60-120 mg deep SC every 4 weeks

FDA Approved Labeling - Prescribed dose ↗

Extended interval dosing possible

FDA Approved Labeling - Prescribed dose ↗

Duration

Long-term / chronic use

Administration

Deep subcutaneous injection

When and how is Lanreotide taken?

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

What are the side effects of Lanreotide?

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Diarrhea
  • ●Abdominal pain
  • ●Nausea
  • ●Injection site reactions
  • ●Gallstones
  • ●Hyperglycemia or hypoglycemia
  • ●Bradycardia and other heart rate or conduction effects
  • ●Thyroid function changes

References

Research This Peptide Further

Frequently Asked Questions

What does Lanreotide do?

Lanreotide (development code BIM-23014) is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. The FDA approved it for acromegaly in 2007, for gastroenteropancreatic neuroendocrine tumors in 2014, and for carcinoid syndrome in 2017. Generic versions now exist alongside Ipsen's Somatuline Depot. It is established prescription medicine, not an experimental compound.

How does Lanreotide work?

Like octreotide, lanreotide binds the somatostatin receptor family with a strong preference for SSTR2 and SSTR5 and weak binding to SSTR1, SSTR3, and SSTR4. Hitting SSTR2 and SSTR5 on pituitary cells suppresses growth hormone release, which lowers IGF-1 and controls acromegaly. On neuroendocrine tumor cells, which often carry plenty of these same receptors, the drug both reduces hormone over-secretion and exerts a direct antiproliferative, growth-slowing effect. The supersaturated gel formulation forms a depot under the skin that releases the peptide slowly, so a single injection lasts about four weeks. The clinical logic is identical to octreotide: a stable, receptor-selective stand-in for a hormone the body destroys in minutes.

Is Lanreotide FDA approved?

Yes, Lanreotide is FDA approved. FDA Approved - Acromegaly (2007), GEP-NETs (2014) and carcinoid syndrome (2017). 2026 supply note: Cipla's generic lanreotide, made under contract by Pharmathen in Greece, was recalled in early 2026 (lack of sterility assurance, Class II) and the Pharmathen site was reported placed under an FDA import alert in April 2026. Ipsen's Somatuline Depot is a separate product and Ipsen said in January 2026 it could supply patient needs.

Is Lanreotide banned in sport?

Not on the WADA Prohibited List (2026).

What are the side effects of Lanreotide?

Reported side effects include: Diarrhea, Abdominal pain, Nausea, Injection site reactions, Gallstones. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Lanreotide?

Community-reported common dose: 60-120 mg every 4 weeks (Every 4 weeks). Range: 60-120 mg per administration. Administration: Deep subcutaneous injection. Prescription drug. Dose set by prescriber per label. Not medical advice.

Related Peptides

Peptides commonly compared with Lanreotide or used in similar applications.

Pegvisomant

FDA

Pegvisomant (brand name Somavert) flips the usual acromegaly strategy on its head: instead of telling the tumor to make less growth hormone, it blocks growth hormone's receptor on target tissues directly. It is a PEGylated, genetically modified version of human growth hormone that acts as a receptor antagonist, FDA-approved in 2003 for acromegaly patients who do not respond well to surgery or other drugs. It is the single most effective option for normalizing IGF-1, which is why it is a key second-line therapy.

Hormonal

Leuprolide

FDA

Leuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide far more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug (first US approval 1985), not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.

Hormonal

Octreotide

FDA

Octreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).

Hormonal

Macimorelin

FDA

Macimorelin (brand name Macrilen) is an orally active ghrelin receptor agonist used as a diagnostic test, not a treatment. You drink a single dose, then doctors measure how much growth hormone the pituitary releases to diagnose adult growth hormone deficiency. It was FDA approved in December 2017 as the first oral diagnostic agent for that condition.

Hormonal

HMG

FDA

HMG (human menopausal gonadotropin, sold as menotropins under the brand Menopur) is a purified hormone mix extracted from the urine of postmenopausal women. Each standard vial carries 75 IU of FSH activity and 75 IU of LH activity, with most of the LH activity coming from hCG. It is an FDA-approved fertility drug used to stimulate egg development in IVF, and it is also used, mostly off-label in the US, together with hCG to kick-start sperm production in men whose pituitary does not make enough FSH and LH. This one has decades of real clinical use behind it.

Hormonal

Triptorelin

FDA

Triptorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) with a D-tryptophan swapped in at position 6, which makes it far more potent and longer-lasting than the natural hormone. As a long-acting depot it is FDA-approved to shut down testosterone in advanced prostate cancer (Trelstar) and to pause early puberty in children (Triptodur), and in Europe it is sold as Decapeptyl, including a short-acting 0.1 mg form used in IVF. In men's health circles it is known for something else: a single small dose used to 'restart' testosterone after steroid use. That idea rests on very little published evidence.

Hormonal

Want updates on Lanreotide research?

Get an email when we add new research here, when it is back in stock, or when the price drops.